Previous close | 167.80 |
Open | 167.66 |
Bid | 166.71 x 800 |
Ask | 166.50 x 800 |
Day's range | 165.57 - 169.29 |
52-week range | 130.96 - 182.89 |
Volume | |
Avg. volume | 5,630,903 |
Market cap | 296.212B |
Beta (5Y monthly) | 0.56 |
PE ratio (TTM) | 61.28 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 6.20 (3.71%) |
Ex-dividend date | 12 Apr 2024 |
1y target est | N/A |
Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday. Cigna said it will stock high- and low-concentration biosimilar versions of Humira from drugmakers including Boehringer Ingelheim, Teva and Alvotech at its Accredo pharmacy.
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.